NASDAQ GS | VYGR (Common Stock)


 0.59 (3.93%)

Data as of: 12/09/16  4:00 p.m. ET

Investor Overview

Webcast ImageWebcast
Voyager Therapeutics Conference Call (Replay)
12/07/16 at 4:30 p.m. ET
Voyager Therapeutics Conference Call
Wednesday, December 7, 2016 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile

Voyager Therapeutics is developing life-changing gene therapies for fatal and debilitating diseases of the central nervous system. Our founders include scientific and clinical leaders in the fields of adeno-associated virus (AAV) gene therapy, expressed RNA interference and neuroscience. Our management team has deep expertise and a track record of building exceptional life science companies. More >>

Recent NewsMore >>
December 09, 2016
Voyager Therapeutics to Attend Upcoming Investor Conference
December 07, 2016
Voyager Therapeutics Announces Positive Interim Results from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease
November 29, 2016
Voyager Therapeutics and REGENXBIO Announce Exercise of Options for Rights to NAV Vectors
Upcoming EventsMore >>
Voyager Therapeutics Inc at BMO Prescriptions for Success Healthcare Conference
LocationNew York, NY
Data provided by Nasdaq. Minimum 15 minutes delayed.